The USFDA recently granted accelerated approval to Celgene Corporation’s Supplemental New Drug Application (sNDA) for THALOMID (thalidomide) in combination with dexamethasone for the treatment of newly diagnosed multiple myeloma.
In the United States (affecting approximately 50,000 people) multiple myeloma is the second most common blood cancer. Multiple myeloma is an incurable blood cancer and THALOMID provides physicians and patients with another therapy option which is available through a THALOMID Education and Prescribing Safety System, called S.T.E.P.S.®.
Read more at Celgene press release.
.jpg)
Comment Preview